NASHVILLE, Tenn.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/acquisition?src=hash" target="_blank"gt;#acquisitionlt;/agt;–National Seating & Mobility (NSM), the leading provider of complex rehab…
VivaQuant RX-1 Wearable All-in-One Mobile Cardiac Telemetry Unit and Event Monitor FDA Cleared
VivaQuant, a company based in the Minneapolis/St. Paul area, won FDA clearance for its RX-1 cardiac patient monitor. The device is unique in that it is able to operate as a Mobile Cardiac Telemetry unit or Event Monitor, all while transmitting its readings for remote analysis. The system gives cardiologists the ability to free up […]
Uncategorized
VIDEO: Eyenovia progressing in mydriasis, glaucoma, myopia treatments
SAN DIEGO ― At the Ophthalmology Innovation Summit, Sean Ianchulev, MD, MPH, CEO of Eyenovia, discusses the company’s technology in development for mydriasis, as well as glaucoma and myopia treatments.
Watchful Waiting OK in Diabetic Macular Edema With Good Vision
New trial suggests no difference in risk for vision loss over 2 years with aflibercept, laser treatment, or observation; experts stress importance of adherence to follow-up and tight glycemic control. Medscape Medical News
Compulink Previews New User Interface for its Ophthalmology SMART EHR at ASCRS-ASOA 2019
NEWBURY PARK, Calif.–(BUSINESS WIRE)–Compulink previews new user interface for its Ophthalmology SMART EHR at ASCRS-ASOA 2019.
Eyenukの糖尿病網膜症向けAIアイ・スクリーニング・システムが前向き多施設ピボタル臨床試験で卓越した性能を証明
ロサンゼルス–(BUSINESS WIRE)–（ビジネスワイヤ） — 人工知能（AI）医療技術・サービスの世界的企業で、AIアイ・スクリーニング（AI Eye Screening™）向け実臨床アプリケーションのリーダー企業のEyenuk, Inc.は本日、EyeArt®（アイアート）AIアイ・スクリーニング・システムを対象に、糖尿病網膜症（DR）の自律的検出を検証した当社のランドマーク試験としての前向き多施設ピボタル臨床試験の結果を発表しました。失明病となるDRは、罹患者が2030年までに世界…